Top Medical Searches

Spark’s planned price for Luxturna gene therapy for rare blindness too high: ICER

(Reuters) – The proposed price for Spark Therapeutics Inc’s groundbreaking one-time gene therapy for a rare form of blindness is far too high, an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday.

 Read more…

Be Sociable, Share!
January 12th, 2018 Posted in Drug
Copyright 2008 © Drugs and Diseases. Developed by Axilosoft
Home | About Us | Privacy Policy | Contact Us